



# NewCo Licensing

# Antibodies

## Small Molecules

## ADCs

## Recomb Protein



Target	Indications	Preclinical	Ph I	Ph II	Ph III	Commercial
LAG3	solid tumors and lymphoma; autoimmune					
EGFR; CD3	metastatic breast cancer; gastric cancer					
Enzyme-controlled TAA; CD3	solid tumors					
CD19; CD3; CD28	B-cell malignant hematological tumors; autoimmune diseases including SLE, RA, Myasthenia gravis, etc.					
IL-2 prodrug	solid tumors					
ROR1; CD3	lymphoma; breast cancer					
TAA; CD3	hepatocellular carcinoma					
PD-1/IL-15 cytokine antibody conjugate	solid tumors					
CD3 bispecific antibody prodrug	solid tumors					
HER2; Trop2	breast cancer; cervical cancer; gastric cancer					
PD-L1; VEGF	lung cancer; breast cancer					

Antibodies

**Small Molecules**

ADCs

Recomb Protein



Target	Indications	Preclinical	Ph I	Ph II	Ph III	Commercial
KV1.3 (Topical)	atopic dermatitis					
cMyc	pancreatic cancer					
PI3K-mTOR-Akt pathway	melanoma; esophageal cancer, colorectal cancer					
mTORC2	neuroendocrine tumors; lung cancer; breast cancer					
FXIa	thrombus					
KV1.3 (Oral)	inflammatory bowel disease					
cMyc	gynecological tumors					

Antibodies

Small Molecules

**ADCs**

Recomb Protein



Target

Indications

Preclinical

Ph I

Ph II

Ph III

Commercial

Nectin-4/Trop2

bladder cancer; cervical cancer; lung cancer



cMet/HER2

pancreatic cancer; lung cancer;  
gastrointestinal  
cancer; renal cancer



Antibodies

Small Molecules

ADCs

**Recomb Protein**



Entity

Indications

Preclinical Ph I Ph II Ph III Commercial

Human II-11

thrombocytopenia caused by  
radiotherapy or chemotherapy



Retepase

acute myocardial infarction



Human EPO

anemia caused by CKD



# Meeting Request

Join us in bridging the gap between Chinese pharmaceutical innovation and global markets. Contact our NewCo team today to explore how we can unlock new possibilities together.



[bde@unibestcn.com](mailto:bde@unibestcn.com)



+86 (0)574 2785 5666



+86 152 5057 3086